he purpose of this report was to update the 2006 International League Against Epilepsy (ILAE) report and identify the level of evidence for long-term efficacy or effectiveness for antiepileptic drugs (AEDs) as initial monotherapy for patients with newly diagnosed or untreated epilepsy. All applicable articles from July 2005 until March 2012 were identified, evaluated, and combined with the previous ysis (Glauser et al., 2006) to provide a comprehensive update.
The prior ysis methodology was utilized with three modifications: (1) the detectable noninferiority boundary approach was dropped and both failed superiority studies and prespecified noninferiority studies were yzed using a noninferiority approach, (2) the definition of an adequate comparator was clarified and now includes an absolute minimum point estimate for efficacy/effectiveness, and (3) the relationship table between clinical trial ratings, level of evidence, and conclusions no longer includes a recommendation column to reinforce that this review of efficacy/evidence for specific seizure types does not imply treatment recommendations.
This evidence review contains one clarification: The commission has determined that class I superiority studies can be designed to detect up to a 20% absolute (rather than relative) difference in the point estimate of efficacy/effectiveness between study treatment and comparator using an intent-to-treat ysis. Since July, 2005, three class I randomized controlled trials (RCT) and 11 class III RCTs he been published. The combined ysis (1940-2012) now includes a total of 64 RCTs (7 with class I evidence, 2 with class II evidence) and 11 meta-yses.
New efficacy/effectiveness findings include the following: levetiracetam and zonisamide he level A evidence in s with partial onset seizures and both ethosuximide and valproic acid he level A evidence in children with childhood absence epilepsy.
There are no major changes in the level of evidence for any other subgroup. Levetiracetam and zonisamide join carbamazepine and phenytoin with level A efficacy/effectiveness evidence as initial monotherapy for s with partial onset seizures. Although ethosuximide and valproic acid now he level A efficacy/effectiveness evidence as initial monotherapy for children with absence seizures, there continues to be an alarming lack of well designed, properly conducted epilepsy RCTs for patients with generalized seizures/epilepsies and in children in general.
These findings reinforce the need for multicenter, multinational efforts to design, conduct, and yze future clinically relevant adequately designed RCTs. When selecting a patient's AED, all relevant variables and not just efficacy and effectiveness should be considered.
提示信源地址
上一页:病因胶质瘤的依据是什么?
下一页:小儿癫痫病哪家该医院好
- 2022-05-03什么是引起中风的原因
- 2022-04-2720160518名医话养生2016:薛征讲兰花的作用
- 2022-04-252013年International抗癫痫联合会抗癫痫药使用指南
- 2022-02-28癫痫病诊断的依据是什么
- 2019-04-20小儿癫痫患者吃什么好
- 上海率先探索异地就医门诊费直接结算
- Diabetes Obes Metab:恩格列净对肝脂肪变性和纤维化标志物的影响及其与心肾结局的关系
- 2016AAN:神经专家发表了有前途的专业见解
- 癫痫患者手术评估新型工具
- 河南:无偿献血者用血费用一站式减免
- FDA批准开浦兰治疗1个月至4岁癫痫儿童
- 癫痫猝死:凶手是谁?
- 月经性癫痫患者妊娠期癫痫控制更好
- 抗癫痫药物预防新发癫痫:任重而道远
- 癫痫患者停药问题解决了吗?最新的预测模型已经发布!
- 被WHO推荐,IVD国产替代品在结核病诊断领域取得了新的成果
- 罕见病例:自发性颞极性扩张伴癫痫发作
- Medpage Today:不同类型的抗癫痫药物更有利
- Circ Ep:左室肥厚高血压患者新发房颤增加SCD风险
- 癫痫治疗 中医治疗癫痫不用担心
- 癫痫治疗障碍仍难以克服
- 三庚酸酯可治疗1型转运体缺陷综合征
- 癫痫治愈费用
- 女性癫痫的治疗多少钱
- PLoS ONE:新的合成蛋白能快速激活免疫系统抵抗流感
- 世界癫痫日 | 科学防治 标准诊疗 告别癫痫
- 羊角病能生孩子吗?
- 预测癫痫患者再入院风险
- UCB的Vimpat癫痫新适应症在美国获批
- 英国竞争监管机构指控辉瑞癫痫药品价格过高
- 黑芝麻的营养价值 吃黑芝麻的好处
- 化疗小儿癫痫病要多钱
- 2015年第31届国际中风大会(IEC)
- 幼儿癫痫病的副作用
- 痉挛发作连撞多车,痉挛患者到底能不能开车上路?
- 癫痫病诊断的依据是什么
- 天使科普:小儿癫痫有哪些症状形态?
- 癫痫病的常见肺癌因素有什么
- 手术治疗局灶耐药性哮喘效果佳
- 真正归因于癫痫病的原因是什么呢
- 【病患情报站】五花八门的药物禁忌证,临床应用该听谁的?
- 治疗癫痫病小儿哪些好啊
- 大脑极度放电就等于得了癫痫病么?
- 临床如何诊断到底患有轻度癫痫
- 男性为什么会患癫痫病 癫痫病症状